Creative Planning
SRPT icon

Creative Planning’s Sarepta Therapeutics SRPT Stock Holding History

Creative Planning’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-100
Closed -$1K – 4721
2016
Q2 		$1K Buy
+100
New +$1.85K ﹤0.01% 4209

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Creative Planning's SRPT Position: Q2 2026 in Review

Creative Planning reduced its Sarepta Therapeutics (SRPT) stake by 26% in Q2 2026, selling an estimated $413K and leaving 62,364 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2549.

Creative Planning first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $16.7M in Q2 2019. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Creative Planning held 62,364 shares of Sarepta Therapeutics worth $1.12M as of Q2 2026.
  • Creative Planning sold 21,824 Sarepta Therapeutics shares in Q2 2026, an estimated $413K.
  • Sarepta Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2549 holding.
  • Creative Planning first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Creative Planning's Sarepta Therapeutics position peaked at $16.7M in Q2 2019.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.